MRKR — Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 5
- Website: https://www.markertherapeutics.com
Latest SEC filings for MRKR
- 10-Q — 2026-05-15
- 8-K — 2026-05-04
- ARS — 2026-03-20
- 8-K — 2026-03-19
- 10-K — 2026-03-18
- 8-K — 2026-02-09
- 8-K — 2025-11-14
- 10-Q — 2025-11-13
- 8-K — 2025-11-05
- 8-K — 2025-10-06
Latest MRKR news
- — Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer (GlobeNewswire Inc.)
- — All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy (Zacks Investment Research)
- — New Strong Buy Stocks for October 16th (Zacks Investment Research)
Educational tool only — not investment advice.